Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...
Get the detailed quarterly/annual income statement for X4 Pharmaceuticals, Inc. (XFOR). Find out the revenue, expenses and profit or loss over the last fiscal year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results